abstract |
Provided is a method of determining the prognosis of a patient undergoing treatment for Alzheimer's disease, the method comprising: contacting Aß peptide with a patient tissue sample; detecting immunoreactivity of the patient tissue sample for Aß peptide; and comparing the detected immunoreactivity with a baseline control level of tissue sample immunoreactivity; wherein a significantly higher patient tissue sample immunoreactivity as compared to a baseline control level of tissue sample immunoreactivity is indicative of a prognosis of improved status with respect to said Alzheimer's disease. |